Urotensin II receptor expression in patients with ulcerative colitis: a pilot study.

Antonietta G Gravina, Marcello Dallio, Concetta Tuccillo, Marco Martorano, Ludovico Abenavoli, Francesco Luzza, Paola Stiuso, Stefania Lama, Paolo Grieco, Francesco Merlino, Michele Caraglia, Carmelina Loguercio, Alessandro Federico
{"title":"Urotensin II receptor expression in patients with ulcerative colitis: a pilot study.","authors":"Antonietta G Gravina,&nbsp;Marcello Dallio,&nbsp;Concetta Tuccillo,&nbsp;Marco Martorano,&nbsp;Ludovico Abenavoli,&nbsp;Francesco Luzza,&nbsp;Paola Stiuso,&nbsp;Stefania Lama,&nbsp;Paolo Grieco,&nbsp;Francesco Merlino,&nbsp;Michele Caraglia,&nbsp;Carmelina Loguercio,&nbsp;Alessandro Federico","doi":"10.23736/S1121-421X.19.02602-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Urotensin II (U-II) is a vasoactive peptide that interacts with a specific receptor named UTR. Recently, our group has demonstrated increased UTR expression in both human colon adenocarcinoma cell lines and adenomatous polyps, as well as in colon carcinoma samples if compared to healthy colon samples of the same patients. We also showed that an UTR agonist induced an increase in colon adenocarcinoma cell growth in vitro, whereas the UTR block with a specific antagonist caused an inhibition of their growth and an inhibition of about 50% of both motility and cell invasion. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) associated with an increased baseline risk for colon cancer compared with the general population, and this risk is mostly attributed to chronic inflammation and immune dysregulation. This risk increases along with the duration of the disease, as demonstrated by many studies. There are no UTR expression data related to UC, and we therefore evaluated UTR expression in ill colon biopsies and in healthy colon ones of patients with UC and colon biopsies of healthy patients.</p><p><strong>Methods: </strong>We enrolled, prior to informed consent, 11 patients (5 males and 6 females, age range 29-75 years, median age 52 years) with first UC diagnosis compared to 11 healthy controls (6 males and 5 females, age range 30-78 years, median age 55 years). We have therefore sampled inflammatory and healthy tissue in UC patients. We have also taken colic tissue samples in healthy subjects. Evaluation of receptor expression was performed by reverse transcription-polymerase chain reaction (RT-PCR), Western Blot analysis. The ANOVA Test (P<0.05) was used for statistical analysis.</p><p><strong>Results: </strong>We found: 1) increased expression of UTR in 11/11 UC patients with ill mucosa biopsies compared to healthy controls in RT-PCR and in Western Blot analysis; 2) increased UTR expression in 11/11 UC patients with ill colon biopsies compared to the results obtained from healthy colon biopsies of the same patients both in RT-PCR and in Western Blot analysis; 3) increased UTR expression in 9/11 UC patients healthy colon biopsy specimens compared to healthy controls.</p><p><strong>Conclusions: </strong>UTR could be considered as an inflammatory UC disease marker because its expression is greater in the mucosa of ill colon than in the healthy colon of the same patients and compared to healthy controls.</p>","PeriodicalId":74201,"journal":{"name":"Minerva gastroenterologica e dietologica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva gastroenterologica e dietologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S1121-421X.19.02602-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background: Urotensin II (U-II) is a vasoactive peptide that interacts with a specific receptor named UTR. Recently, our group has demonstrated increased UTR expression in both human colon adenocarcinoma cell lines and adenomatous polyps, as well as in colon carcinoma samples if compared to healthy colon samples of the same patients. We also showed that an UTR agonist induced an increase in colon adenocarcinoma cell growth in vitro, whereas the UTR block with a specific antagonist caused an inhibition of their growth and an inhibition of about 50% of both motility and cell invasion. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) associated with an increased baseline risk for colon cancer compared with the general population, and this risk is mostly attributed to chronic inflammation and immune dysregulation. This risk increases along with the duration of the disease, as demonstrated by many studies. There are no UTR expression data related to UC, and we therefore evaluated UTR expression in ill colon biopsies and in healthy colon ones of patients with UC and colon biopsies of healthy patients.

Methods: We enrolled, prior to informed consent, 11 patients (5 males and 6 females, age range 29-75 years, median age 52 years) with first UC diagnosis compared to 11 healthy controls (6 males and 5 females, age range 30-78 years, median age 55 years). We have therefore sampled inflammatory and healthy tissue in UC patients. We have also taken colic tissue samples in healthy subjects. Evaluation of receptor expression was performed by reverse transcription-polymerase chain reaction (RT-PCR), Western Blot analysis. The ANOVA Test (P<0.05) was used for statistical analysis.

Results: We found: 1) increased expression of UTR in 11/11 UC patients with ill mucosa biopsies compared to healthy controls in RT-PCR and in Western Blot analysis; 2) increased UTR expression in 11/11 UC patients with ill colon biopsies compared to the results obtained from healthy colon biopsies of the same patients both in RT-PCR and in Western Blot analysis; 3) increased UTR expression in 9/11 UC patients healthy colon biopsy specimens compared to healthy controls.

Conclusions: UTR could be considered as an inflammatory UC disease marker because its expression is greater in the mucosa of ill colon than in the healthy colon of the same patients and compared to healthy controls.

溃疡性结肠炎患者尿紧张素II受体表达:一项初步研究。
背景:尿紧张素II (U-II)是一种血管活性肽,可与一种名为UTR的特异性受体相互作用。最近,我们的研究小组已经证明,与同一患者的健康结肠样本相比,UTR在人类结肠腺癌细胞系和腺瘤性息肉以及结肠癌样本中的表达都有所增加。我们还发现,UTR激动剂在体外诱导结肠癌细胞生长增加,而UTR阻断与特定拮抗剂导致其生长抑制,并抑制约50%的运动和细胞侵袭。溃疡性结肠炎(UC)是一种炎症性肠病(IBD),与普通人群相比,结肠癌的基线风险增加,这种风险主要归因于慢性炎症和免疫失调。正如许多研究所证明的那样,这种风险随着疾病的持续时间而增加。没有与UC相关的UTR表达数据,因此我们评估了UC患者的病变结肠活检、健康结肠活检和健康患者结肠活检中UTR的表达。方法:在知情同意之前,我们招募了11例首次诊断为UC的患者(5男6女,年龄29-75岁,中位年龄52岁)与11例健康对照(6男5女,年龄30-78岁,中位年龄55岁)。因此,我们对UC患者的炎症组织和健康组织进行了取样。我们也采集了健康受试者的肠绞痛组织样本。采用逆转录聚合酶链反应(RT-PCR)、Western Blot分析受体表达。方差分析(结果:我们发现:1)在RT-PCR和Western Blot分析中,与健康对照组相比,11/11粘膜活检不良的UC患者中UTR的表达增加;2)在11/11 UC患者中,与同一患者健康结肠活检结果相比,在RT-PCR和Western Blot分析中,UTR表达增加;3)与健康对照组相比,9/11 UC患者健康结肠活检标本中UTR表达增加。结论:UTR在患病结肠粘膜中的表达高于同一患者健康结肠粘膜中的表达,与健康对照相比,UTR可被认为是炎症性UC的疾病标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信